Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors

Transplant Infectious Disease

Volumn 7, Issue 2, 2005, Pages 57-62

  Shah, Tahir ^a,b   Lai, W K ^a   Mutimer, D ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cost analysis; Cytomegalovirus; Ganciclovir; Liver transplant; Prophylaxis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PHYSICIAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CHEMOPREVENTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS; TREATMENT OUTCOME;

EID: 25144510397     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2005.00093.x     Document Type: Article

References (15)

1. FALAGAS ME, ARBO M, RUTHAZER R, GRIFFITH JL. Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant patients. Transplantation 1997:63:1595-1601.
2. O'GRADY JG, ALEXANDER GJ, SUTHERLAND S, WILLIAMS R. CMV infection and donor/recipient HLA antigens: independent co-factors in the pathogenesis of vanishing bile duct syndrome after liver transplantation. Lancet 1988:2:302-305.
3. DALY JS, KOPASZ A, ANANDAKRISHNAN R, et al. Pre-emptive strategy for ganciclovir administration against cytomegalovirus in liver transplant recipients. Am J Transplant 2002:2:955-958.
4. NOBLE S, FAULDS D. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998:56:115-146.
5. GANE E, SALIBA F, VALDECASAS GJC, et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. Lancet 1997:350:1729-1733.
6. RUBIN RH, KEMMERLY SA, CONTI D, et al. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis. Transpl Infect Dis 2000:2:99-100.
7. PAYA CV, WILSON JA, ESPY MJ, et al. Pre-emptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomised, placebo controlled trial. J Infect Dis 2002:185:854-860.
8. SEU P, WINSTON DJ, HOLT CD, KALDAS F, BUSUTTIL RW. Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation 1997:64:1614-1617.
9. WINSTON DJ, IMAGAWA DK, HOLT CD, KALDAS F, SHAKEDA, BUSUTTIL RW. Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995:60:1357-1360.
10. SINGHAL S, KHAN OA, BRAMBLE RA, MUTIMER DJ. Cytomegalovirus disease following liver transplantation: an analysis of prophylaxis strategies. J Infect 2003:47:104-109.
11. WINSTON DJ, BUSUTTIL RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003:75:229-233.
12. BOIVIN G, GOYETTE N, GILBERT C, et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004:189:1615-1618.
13. SINGH N, YU VL, MIELES L, et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994:120:375-381.
14. KUNZLE N, PETIGNAT C, FRANCIOLI P, et al. Pre-emptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity. Transpl Infect Dis 2000:2:118-126.
15. WINSTON DJ, BUSUTTIL RW. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 2004:77: 305-308.